Cannabis stocks face sharp decline following DOJ rescheduling decision. The Department of Justice moved only FDA-approved and state-licensed medical marijuana to Schedule III, disappointing investors who anticipated broader industry reform. Major players including Cronos Group, Aurora Cannabis, Canopy Growth, Tilray, and Organigram experienced significant selloffs as the market reacted to the limited scope of reclassification. The narrow approach means most recreational cannabis remains federally illegal, constraining banking access and interstate commerce for the broader industry. Analysts note the rescheduling provides minimal immediate benefit to most cannabis operators since few products meet the strict FDA approval and state licensing requirements. The decision highlights the disconnect between state-level legalization and federal policy, leaving the industry in regulatory limbo.
Post from MarketNews_en
Log in to interact with content.